1
|
Podvin B, Magierowicz M, Soenen V, Dumezy F, Duployez N, Charpentier A. Oligomonocytic chronic myelomonocytic leukemia is eligible to MDS-score and not Mono-dysplasia score. Int J Lab Hematol 2024. [PMID: 38644333 DOI: 10.1111/ijlh.14294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Accepted: 04/11/2024] [Indexed: 04/23/2024]
Affiliation(s)
- Benjamin Podvin
- Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France
- Laboratory of Hematology, CHU Lille, Lille, France
| | - Marion Magierowicz
- Laboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France
| | | | | | - Nicolas Duployez
- Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France
- Laboratory of Hematology, CHU Lille, Lille, France
| | - Agnès Charpentier
- Laboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France
| |
Collapse
|
2
|
Podvin B, Soenen V, Dumezy F, Herlem J, Berthon C, Guermouche H, Thibaud V, Pascal L, Duployez N, Charpentier A. A new combination of monocytic scores to support diagnosis of chronic myelomonocytic leukemia according to novel classifications. Int J Lab Hematol 2023; 45:791-794. [PMID: 36967295 DOI: 10.1111/ijlh.14067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Accepted: 03/04/2023] [Indexed: 03/29/2023]
Affiliation(s)
- Benjamin Podvin
- Laboratory of Hematology, CHU Lille, Lille, France
- Laboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France
| | | | | | - Julien Herlem
- Laboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France
| | - Céline Berthon
- CHU Lille, Department of Hematology, Huriez Hospital, Lille, France
| | | | - Vincent Thibaud
- Hematology Department, Hospital Group of Lille Catholic University, Lille, France
| | - Laurent Pascal
- Hematology Department, Hospital Group of Lille Catholic University, Lille, France
| | - Nicolas Duployez
- Laboratory of Hematology, CHU Lille, Lille, France
- Plasticity and Resistance to Therapies, Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020-UMR1277-Canther-Cancer Heterogeneity, Lille, France
| | - Agnès Charpentier
- Laboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France
| |
Collapse
|
3
|
Gazeau N, Derrieux C, Nibourel O, Berthon C, Grardel N, Goursaud L, Boyer T, Dumezy F, Coiteux V, Quesnel B, Preudhomme C, Roche-Lestienne C, Duployez N. Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia. Leukemia 2020; 34:2230-2233. [PMID: 31988437 DOI: 10.1038/s41375-020-0715-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Revised: 01/08/2020] [Accepted: 01/14/2020] [Indexed: 11/09/2022]
Affiliation(s)
- Nicolas Gazeau
- CHU Lille, Hematology Department, Claude Huriez Hospital, F-59000, Lille, France
| | | | - Olivier Nibourel
- CHU Lille, Laboratory of Hematology, F-59000, Lille, France
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
| | - Céline Berthon
- CHU Lille, Hematology Department, Claude Huriez Hospital, F-59000, Lille, France
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
| | | | - Laure Goursaud
- CHU Lille, Hematology Department, Claude Huriez Hospital, F-59000, Lille, France
| | - Thomas Boyer
- CHU Lille, Laboratory of Hematology, F-59000, Lille, France
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
| | - Florent Dumezy
- CHU Lille, Laboratory of Hematology, F-59000, Lille, France
| | - Valérie Coiteux
- CHU Lille, Hematology Department, Claude Huriez Hospital, F-59000, Lille, France
| | - Bruno Quesnel
- CHU Lille, Hematology Department, Claude Huriez Hospital, F-59000, Lille, France
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
| | - Claude Preudhomme
- CHU Lille, Laboratory of Hematology, F-59000, Lille, France
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
| | - Catherine Roche-Lestienne
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
- CHU Lille, Institute of Medical Genetics, Jeanne de Flandre Hospital, F-59000, Lille, France
| | - Nicolas Duployez
- CHU Lille, Laboratory of Hematology, F-59000, Lille, France.
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France.
| |
Collapse
|
4
|
Fournier B, Balducci E, Duployez N, Clappier E, Cuccuini W, Arfeuille C, Caye-Eude A, Delabesse E, Bottollier-Lemallaz Colomb E, Nebral K, Chrétien ML, Derrieux C, Cabannes-Hamy A, Dumezy F, Etancelin P, Fenneteau O, Frayfer J, Gourmel A, Loosveld M, Michel G, Nadal N, Penther D, Tigaud I, Fournier E, Reismüller B, Attarbaschi A, Lafage-Pochitaloff M, Baruchel A. B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL. Front Oncol 2019; 9:1374. [PMID: 31921638 PMCID: PMC6914849 DOI: 10.3389/fonc.2019.01374] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2019] [Accepted: 11/21/2019] [Indexed: 02/03/2023] Open
Abstract
Background: B-cell acute lymphoblastic leukemia associated with t(5;14)(q31;q32); IGH-IL3 is an exceptional cause of eosinophilia. The IGH enhancer on 14q32 is juxtaposed to the IL3 gene on 5q31, leading to interleukin-3 overproduction and release of mature eosinophils in the blood. Clinical, biological and outcome data are extremely scarce in the literature. Except for eosinophilia, no relevant common feature has been highlighted in these patients. However, it has been classified as a distinct entity in the World Health Organization classification. Cases Presentation: Eight patients with t(5;14)(q31;q32) treated by French or Austrian protocols were retrospectively enrolled. Array comparative genomic hybridization, multiplex ligation-dependent probe amplification or genomic PCR search for IKZF1 deletion were performed in 7. Sixteen patients found through an exhaustive search in the literature were also analyzed. For those 24 patients, median age at diagnosis is 14.3 years with a male predominance (male to female ratio = 5). Eosinophilia-related symptoms are common (neurologic in 26%, thromboembolic in 26% or pulmonary in 50%). Median white blood cells count is high (72 × 109/L) and linked to eosinophilia (median: 32 × 109/L). Peripheral blasts are present at a low level or absent (median: 0 × 109/L; range: 0–37 × 109/L). Bone marrow morphology is marked by a low blast infiltration (median: 42%). We found an IKZF1 deletion in 5 out of 7 analyzable patients Outcome data are available for 14 patients (median follow-up: 28 months): 8 died and 6 are alive in complete remission. Some of these features are concordant with those seen in patients with other IGH-rearranged B-cell acute lymphoblastic leukemias: young age at onset, male sex, low blast count, high incidence of IKZF1 deletion and intermediate prognosis. Conclusion: Based on shared epidemiological and biological features, B-cell acute lymphoblastic leukemia with t(5;14)(q31;q32) is a peculiar subset of IGH-rearranged B-cell acute lymphoblastic leukemia with an intermediate prognosis and particular clinical features related to eosinophilia.
Collapse
Affiliation(s)
- Benjamin Fournier
- Department of Pediatric Hematology and Immunology, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Estelle Balducci
- Hematology Laboratory, University Hospital Paul-Brousse, Assistance Publique des Hôpitaux de Paris (APHP), Villejuif, France
| | | | - Emmanuelle Clappier
- Hematology Laboratory, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Wendy Cuccuini
- Hematology Laboratory, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Chloé Arfeuille
- Department of Genetics, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Aurélie Caye-Eude
- Department of Genetics, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Eric Delabesse
- Department of Haematology, Institut Universitaire de Cancérologie de Toulouse, CHU de Toulouse, Toulouse, France
| | | | - Karin Nebral
- Children's Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung, Vienna, Austria
| | | | | | - Aurélie Cabannes-Hamy
- Teenagers and Young Adults Hematology Unit, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Florent Dumezy
- Department of Hematology, University Hospital, Lille, France
| | | | - Odile Fenneteau
- Hematology Laboratory, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| | - Jamile Frayfer
- Department of Hematology, Hospital Saint Faron, Meaux, France
| | - Antoine Gourmel
- Department of Pediatric Oncology, Hematology, Immunology, University Hospital of Amiens, Amiens, France
| | - Marie Loosveld
- Hematology Laboratory, Timone Hospital, Assistance Publique-Hôpitaux de Marseille (APHM), CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Aix Marseille University, Marseille, France
| | - Gérard Michel
- Department of Pediatric Hematology, Aix Marseille University, Marseille, France
| | - Nathalie Nadal
- Laboratory of Cytogenetics, University Hospital of Dijon, Dijon, France
| | - Dominique Penther
- Department of Oncology Genetics, Henri Becquerel Center, Rouen, France
| | | | - Elise Fournier
- Department of Hematology, University Hospital, Lille, France
| | - Bettina Reismüller
- Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Andishe Attarbaschi
- Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Marina Lafage-Pochitaloff
- Hematological Cytogenetics Laboratory, Timone Hospital-Assistance Publique-Hôpitaux de Marseille (AP-HM), Aix-Marseille University, Groupe Francophone de Cytogénétique Hématologique (GFCH), Marseille, France
| | - André Baruchel
- Department of Pediatric Hematology and Immunology, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.,Institut Universitaire d'Hématologie, EA-3518, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
| |
Collapse
|
5
|
Touzet L, Dumezy F, Roumier C, Berthon C, Bories C, Quesnel B, Preudhomme C, Boyer T. CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. Cancer Med 2019; 8:1279-1288. [PMID: 30740913 PMCID: PMC6434215 DOI: 10.1002/cam4.2007] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 12/14/2018] [Accepted: 01/15/2019] [Indexed: 01/04/2023] Open
Abstract
CD9 is a cell surface protein and belongs to the tetraspanin family. Its role in carcinomagenesis has been widely studied in solid tumors but remains controversial, depending on the cancer type. Although CD9 seems to be associated with unfavorable outcome and disease progression in acute lymphoblastic leukemia (ALL), this marker has not yet been studied in acute myeloid leukemia (AML). First, we explored its prognostic role and its association with biological factors in a cohort of 112 AML patients treated with intensive chemotherapy. CD9 was expressed in 40% of AML and was associated with a favorable outcome (event‐free survival and relapse‐free survival) in univariate (P = 0.009 and P = 0.048, respectively) and multivariate (P = 0.004 and P = 0.039, respectively) analyses. Interestingly, CD9 expression was different between the more immature physiologic and AML cells (CD34+CD38−) as it was also expressed in AML on putative leukemic stem cells (LSCs) but not on hematopoietic stem cells (HSCs). Hence, CD9 could be a very relevant marker for minimal residual disease (MRD) monitoring in AML based on LSC targeting.
Collapse
Affiliation(s)
- Lucas Touzet
- Laboratory of Hematology, CHU Lille, Lille, France
| | | | | | | | | | | | | | - Thomas Boyer
- Laboratory of Hematology, CHU Lille, Lille, France
| |
Collapse
|
6
|
Fournier E, Inchiappa L, Delattre C, Pignon JM, Danicourt F, Bemba M, Roche-Lestienne C, Daudignon A, Decool G, Roumier C, Dumezy F, Fournier L, Grardel N, Preudhomme C, Duployez N. Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature. Leuk Lymphoma 2019; 60:1827-1830. [DOI: 10.1080/10428194.2018.1562185] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Elise Fournier
- Laboratory of Hematology, CH Dunkerque, Dunkerque, France
- Laboratory of Hematology, CHU Lille, Lille, France
| | | | | | | | | | - Maxime Bemba
- Hematology Department, CH Dunkerque, Dunkerque, France
| | - Catherine Roche-Lestienne
- Department of Medical Genetics, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | | | - Gauthier Decool
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Christophe Roumier
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Florent Dumezy
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Loïc Fournier
- Laboratory of Hematology, CH Dunkerque, Dunkerque, France
| | - Nathalie Grardel
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Claude Preudhomme
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| | - Nicolas Duployez
- Laboratory of Hematology, CHU Lille, Lille, France
- INSERM UMR-S 1172, University of Lille, Lille, France
| |
Collapse
|
7
|
Aanei CM, Jacob MC, Veyrat-Masson R, Picot T, Rosenthal-Allieri MA, Lhoumeau AC, Ticchioni M, Dumezy F, Campos Catafal L. Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation. J Vis Exp 2018. [PMID: 30451229 DOI: 10.3791/57867] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
A working group initiated within the French Cytometry Association (AFC) was developed in order to harmonize the application of multiparameter flow cytometry (MFC) for myeloid disease diagnosis in France. The protocol presented here was agreed-upon and applied between September 2013 and November 2015 in six French diagnostic laboratories (University Hospitals of Saint-Etienne, Grenoble, Clermont-Ferrand, Nice, and Lille and Institut Paoli-Calmettes in Marseille) and allowed the standardization of bone marrow sample preparation and data acquisition. Three maturation databases were developed for neutrophil, monocytic, and erythroid lineages with bone marrow from "healthy" donor individuals (individuals without any evidence of a hematopoietic disease). A robust method of analysis for each myeloid lineage should be applicable for routine diagnostic use. New cases can be analyzed in the same manner and compared against the usual databases. Thus, quantitative and qualitative phenotypic abnormalities can be identified and those above 2SD compared with data of normal bone marrow samples should be considered indicative of pathology. The major limitation is the higher variability between the data achieved using the monoclonal antibodies obtained with the methods based on hybridoma technologies and currently used in clinical diagnosis. Setting criteria for technical validation of the data acquired may help improve the utility of MFC for MDS diagnostics. The establishment of these criteria requires analysis against a database. The reduction of investigator subjectivity in data analysis is an important advantage of this method.
Collapse
Affiliation(s)
| | | | | | - Tiphanie Picot
- Department of Hematology, University Hospital of Saint-Etienne
| | | | | | | | | | | |
Collapse
|
8
|
Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, Feuillard J, Geneviève F, Guérin E, Guy J, Jouault H, Lepelley P, Maynadié M, Solly F, Ballon OW, Preudhomme C, Baruchel A, Dombret H, Ifrah N, Béné MC. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematol Oncol 2017; 36:422-428. [DOI: 10.1002/hon.2488] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 10/13/2017] [Accepted: 11/06/2017] [Indexed: 01/17/2023]
Affiliation(s)
| | - Lydia Campos
- Hematology Biology; University Hospital; Saint Etienne France
| | - Kaoutar Allou
- Hematology Biology; University Hospital; Bordeaux France
| | | | | | | | | | | | | | - Julien Guy
- Hematology Biology; University Hospital; Dijon France
| | | | | | - Marc Maynadié
- Hematology Biology; University Hospital; Dijon France
| | - Françoise Solly
- Hematology Biology; University Hospital; Saint Etienne France
| | | | | | - André Baruchel
- Hematology Department; Hôpital Robert Debré; Paris France
| | - Hervé Dombret
- Hematology Department; Hôpital Saint Louis; Paris France
| | - Norbert Ifrah
- Hematology Department; University Hospital; Angers France
| | - Marie C. Béné
- Hematology Biology; University Hospital; Nantes France
| | | |
Collapse
|
9
|
Lefèvre G, Copin MC, Roumier C, Aubert H, Avenel-Audran M, Grardel N, Poulain S, Staumont-Sallé D, Seneschal J, Salles G, Ghomari K, Terriou L, Leclech C, Morati-Hafsaoui C, Morschhauser F, Lambotte O, Ackerman F, Trauet J, Geffroy S, Dumezy F, Capron M, Roche-Lestienne C, Taieb A, Hatron PY, Dubucquoi S, Hachulla E, Prin L, Labalette M, Launay D, Preudhomme C, Kahn JE. CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica 2015; 100:1086-95. [PMID: 25682606 DOI: 10.3324/haematol.2014.118042] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 02/10/2015] [Indexed: 11/09/2022] Open
Abstract
The CD3(-)CD4(+) lymphoid variant of hypereosinophilic syndrome is characterized by hypereosinophilia and clonal circulating CD3(-)CD4(+) T cells. Peripheral T-cell lymphoma has been described during this disease course, and we observed in our cohort of 23 patients 2 cases of angio-immunoblastic T-cell lymphoma. We focus here on histopathological (n=12 patients) and immunophenotypic (n=15) characteristics of CD3(-)CD4(+) lymphoid variant of hypereosinophilic syndrome. Atypical CD4(+) T cells lymphoid infiltrates were found in 10 of 12 CD3(-)CD4(+) L-HES patients, in lymph nodes (n=4 of 4 patients), in skin (n=9 of 9) and other extra-nodal tissues (gut, lacrymal gland, synovium). Lymph nodes displayed infiltrates limited to the interfollicular areas or even an effacement of nodal architecture, associated with proliferation of arborizing high endothelial venules and increased follicular dendritic cell meshwork. Analysis of 2 fresh skin samples confirmed the presence of CD3(-)CD4(+) T cells. Clonal T cells were detected in at least one tissue in 8 patients, including lymph nodes (n=4 of 4): the same clonal T cells were detected in blood and in at least one biopsy, with a maximum delay of 23 years between samples. In the majority of cases, circulating CD3(-)CD4(+) T cells were CD2(hi) (n=9 of 14), CD5(hi) (n=12 of 14), and CD7(-)(n=4 of 14) or CD7(low) (n=10 of 14). Angio-immunoblastic T-cell lymphoma can also present with CD3(-)CD4(+) T cells; despite other common histopathological and immunophenotypic features, CD10 expression and follicular helper T-cell markers were not detected in lymphoid variant of hypereosinophilic syndrome patients, except in both patients who developed angio-immunoblastic T-cell lymphoma, and only at T-cell lymphoma diagnosis. Taken together, persistence of tissular clonal T cells and histopathological features define CD3(-)CD4(+) lymphoid variant of hypereosinophilic syndrome as a peripheral indolent clonal T-cell lymphoproliferative disorder, which should not be confused with angio-immunoblastic T-cell lymphoma.
Collapse
Affiliation(s)
- Guillaume Lefèvre
- Institute of Immunology, French Eosinophil Network and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille Department of Internal Medicine - Clinical Immunology Unit and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille
| | - Marie-Christine Copin
- Institute of Pathology and CNRS Unit Research UMR 8161, Lille University Hospital, Université Lille Nord de France, Lille
| | - Christophe Roumier
- Institute of Hematology and Inserm Unit U837, Lille University Hospital, Université Lille Nord de France, Lille
| | - Hélène Aubert
- Department of Dermatology, Nantes University Hospital, Nantes
| | | | - Nathalie Grardel
- Institute of Hematology and Inserm Unit U837, Lille University Hospital, Université Lille Nord de France, Lille
| | - Stéphanie Poulain
- Institute of Hematology and Inserm Unit U837, Lille University Hospital, Université Lille Nord de France, Lille
| | - Delphine Staumont-Sallé
- Department of Dermatology, Lille University Hospital, Université Lille Nord de France, Lille
| | - Julien Seneschal
- Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Diseases and Inserm Unit Research U1035, Bordeaux University Hospital, Bordeaux
| | - Gilles Salles
- Department of Hematology, Lyon Sud University Hospital, Hospices Civils de Lyon, Lyon 1 University, Bron
| | | | - Louis Terriou
- Department of Internal Medicine - Clinical Immunology Unit and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille
| | - Christian Leclech
- Department of Dermatology, Angers University Hospital and UNAM University, Angers
| | | | - Franck Morschhauser
- Department of Internal Medicine, Bicêtre University Hospital - APHP, Paris Sud XI University, Le Kremlin-Bicêtre
| | - Olivier Lambotte
- Department of Hematology, Lille University Hospital, Université Lille Nord de France, Lille
| | - Félix Ackerman
- Department of Hematology, Lille University Hospital, Université Lille Nord de France, Lille
| | - Jacques Trauet
- Institute of Immunology, French Eosinophil Network and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille
| | - Sandrine Geffroy
- Institute of Hematology and Inserm Unit U837, Lille University Hospital, Université Lille Nord de France, Lille
| | - Florent Dumezy
- Institute of Hematology and Inserm Unit U837, Lille University Hospital, Université Lille Nord de France, Lille
| | - Monique Capron
- Inserm Unit Research U995, Lille University Hospital, Université Lille Nord de France, Lille
| | - Catherine Roche-Lestienne
- Institut de Génétique Médicale, Inserm Unit U837, Lille University Hospital, Université Lille Nord de France, Lille
| | - Alain Taieb
- Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Diseases and Inserm Unit Research U1035, Bordeaux University Hospital, Bordeaux
| | - Pierre-Yves Hatron
- Department of Internal Medicine - Clinical Immunology Unit and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille
| | - Sylvain Dubucquoi
- Institute of Immunology, French Eosinophil Network and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille
| | - Eric Hachulla
- Institute of Immunology, French Eosinophil Network and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille Department of Internal Medicine - Clinical Immunology Unit and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille
| | - Lionel Prin
- Institute of Immunology, French Eosinophil Network and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille
| | - Myriam Labalette
- Institute of Immunology, French Eosinophil Network and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille
| | - David Launay
- Institute of Immunology, French Eosinophil Network and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille Department of Internal Medicine - Clinical Immunology Unit and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille
| | - Claude Preudhomme
- Institute of Hematology and Inserm Unit U837, Lille University Hospital, Université Lille Nord de France, Lille
| | - Jean-Emmanuel Kahn
- Institute of Immunology, French Eosinophil Network and Research Unit EA2686, Lille University Hospital, Université Lille Nord de France, Lille Department of Internal Medicine, Foch Hospital and Versailles-Saint-Quentin-en-Yvelines University, Suresnes, France
| | | |
Collapse
|
10
|
Willekens C, Dumezy F, Boyer T, Renneville A, Rossignol J, Berthon C, Cotteau-Leroy A, Mehiaoui L, Quesnel B, Preudhomme C. Linezolid induces ring sideroblasts. Haematologica 2014; 98:e138-40. [PMID: 24186315 DOI: 10.3324/haematol.2013.092395] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|